Texas A&M Health is partnering with ActX, a leading genomic decision support vendor, to bring a precision medicine approach to routine patient care. Through a connection with Texas A&M’s eClinicalWorks Electronic Health Record (EHR), providers will have access to real-time alerts based on patient’s genetics to make the most informed decisions – built into their normal workflow.
Texas A&M is one of the fastest growing academic health centers in the United States – it includes six schools in addition to numerous centers and institutes. Seeking to improve patient outcomes through precision medicine, the Texas A&M Health has gone live with their adoption of ActX Clinical Decision Support.
HealthTech Insights: 983 Group Formed to Deliver Results-Oriented Communications for Leading Technology and Health Innovators
Texas A&M Health is excited to launch this partnership as we continue to expand our clinical offerings in support of our precision medicine initiative and expansion of our interprofessional pharmacogenomics clinic efforts within Texas A&M Health
When patients are tested their results are uploaded into the ActX platform, and become actionable within the eClinicalWorks EHR. When a physician prescribes a medication, an automatic background check against the patient’s genetics occurs, and the physician is alerted if drug efficacy, risk of side effects, or dosing are affected by the patient’s genetics. A genomic profile for each patient is now included as part of the patient chart.
HealthTech Insights: Kansas City Real Estate Investment Manager Scott Asner Raises Awareness Around National Blood Donor Month
“Texas A&M Health is excited to launch this partnership as we continue to expand our clinical offerings in support of our precision medicine initiative and expansion of our interprofessional pharmacogenomics clinic efforts within Texas A&M Health” said Ken Ramos, M.D., Ph.D., Associate Vice President of Health Sciences at the Texas A&M Health Science Center, Executive Director of the Institute of Biosciences and Technology and Director of the Texas A&M Regional Center for Excellence in Cancer Research.
HealthTech Insights: Ancera Unveils Innovative Apollo Food Defense System at IPPE 2025
“We are excited to partner with Texas A&M Health as they bring a precision medicine approach into their system. Thanks to the power of pharmacogenomics and the seamless integration with eClinicalWorks EHR, we believe that their patients and clinicians will substantially benefit and see better health outcomes as a result” said Andrew Ury, M.D., CEO of ActX”.
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prweb
